Old Mission Capital’s GSK GSK Stock Holding History

Old Mission Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.9M	Buy	455,346 +20,255	+5%	+$1.07M	0.38%	32
2026 Q1	$24M	Buy	435,091 +275,181	+172%	+$14.9M	0.38%	35
2025 Q4	$7.84M	Buy	+159,910	New	+$7.46M	0.18%	61
2024 Q4	–	Sell	-332,093	Closed	-$13.6M	–	1029
2024 Q3	$13.6M	Sell	332,093 -60,314	-15%	-$2.47M	0.2%	96
2024 Q2	$15.1M	Buy	392,407 +114,782	+41%	+$4.83M	0.26%	74
2024 Q1	$11.9M	Buy	277,625 +77,994	+39%	+$3.22M	0.2%	91
2023 Q4	$7.4M	Buy	199,631 +122,794	+160%	+$4.41M	0.14%	133
2023 Q3	$2.79M	Buy	+76,837	New	+$2.73M	0.06%	244
2023 Q1	–	Sell	-39,413	Closed	-$1.38M	–	1552
2022 Q4	$1.38M	Buy	+39,413	New	+$1.31M	0.04%	407
2022 Q3	–	Sell	-72,449	Closed	-$3.94M	–	1112
2022 Q2	$3.94M	Buy	72,449 +13,380	+23%	+$739K	0.11%	175
2022 Q1	$3.22M	Buy	+59,069	New	+$3.21M	0.09%	199
2021 Q1	–	Sell	-33,572	Closed	-$1.54M	–	791
2020 Q4	$1.54M	Sell	33,572 -21,467	-39%	-$986K	0.1%	184
2020 Q3	$2.59M	Sell	55,039 -251,445	-82%	-$12.6M	0.2%	117
2020 Q2	$15.6M	Buy	+306,484	New	+$15.7M	1.12%	12
2020 Q1	–	Sell	-352,053	Closed	-$20.7M	–	429
2019 Q4	$20.7M	Buy	352,053 +66,089	+23%	+$3.68M	1.59%	14
2019 Q3	$15.3M	Buy	285,964 +56,868	+25%	+$2.93M	1.9%	7
2019 Q2	$11.5M	Buy	229,096 +188,319	+462%	+$9.45M	1.44%	10
2019 Q1	$2.13M	Buy	+40,777	New	+$2.04M	0.36%	57
2018 Q3	–	Sell	-52,695	Closed	-$2.65M	–	293
2018 Q2	$2.65M	Sell	52,695 -1,185	-2%	-$59.7K	0.29%	47
2018 Q1	$2.63M	Sell	53,880 -53,845	-50%	-$2.51M	0.35%	53
2017 Q4	$4.78M	Buy	+107,725	New	+$4.98M	0.31%	58
2017 Q3	–	Sell	-19,599	Closed	-$1.06M	–	369
2017 Q2	$1.06M	Buy	+19,599	New	+$1.04M	0.13%	113
2017 Q1	–	Sell	-102,138	Closed	-$4.92M	–	392
2016 Q4	$4.92M	Buy	+102,138	New	+$5.05M	0.38%	48
2016 Q2	–	Sell	-15,481	Closed	-$785K	–	338
2016 Q1	$785K	Buy	+15,481	New	+$771K	0.08%	134
2015 Q1	–	Sell	-45,806	Closed	-$2.45M	–	246
2014 Q4	$2.45M	Buy	+45,806	New	+$2.56M	0.42%	44

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Old Mission Capital's GSK Position: Q2 2026 in Review

Old Mission Capital increased its GSK (GSK) stake by 4.7% in Q2 2026, buying an estimated $1.07M and bringing the position to 455,346 shares worth $23.9M. The position accounts for 0.38% of the portfolio, ranked #32.

Old Mission Capital first reported a position in GSK in Q4 2014 and has held it in 25 quarters since. The position peaked at $24M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Old Mission Capital held 455,346 shares of GSK worth $23.9M as of Q2 2026.
Old Mission Capital bought 20,255 GSK shares in Q2 2026, an estimated $1.07M.
GSK made up 0.38% of Old Mission Capital's portfolio in Q2 2026, its #32 holding.
Old Mission Capital first reported a position in GSK in Q4 2014 and has held it in 25 quarters since.
Old Mission Capital's GSK position peaked at $24M in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Old Mission Capital's 13F filing for Q2 2026, filed 14 Aug 2026.